Actively Recruiting
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
Led by University of Mississippi Medical Center · Updated on 2025-07-04
60
Participants Needed
1
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.
CONDITIONS
Official Title
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 to 75 years old
- Normal kidney function (for healthy participants)
- No heart failure (for healthy participants)
- Body Mass Index (BMI) 25-30 kg/m2 (for healthy participants)
- eGFR at least 60 mL/min/1.73m2 (for obese participants)
- BMI greater than 35 kg/m2 (for obese participants without HFpEF)
- Diagnosis of Heart Failure with preserved Ejection Fraction (HFpEF) with LVEF > 55% and specific heart failure scores (for obese participants with HFpEF)
You will not qualify if you...
- Diagnosis of chronic illness
- eGFR less than 60 mL/min/1.73m2
- Pregnancy or breastfeeding
- History of allergic reaction to iodine-based contrast dyes
- Hemoglobin levels less than 7 mg/dL
- Acute illness or hospitalization within the last 3 months
- Unable to stop NSAID medications
- Certain comorbid conditions including multiple myeloma, amyloidosis, pheochromocytoma, sickle cell disease, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Current use of nicotine or recreational drugs
- Chronic alcohol use
- For HFpEF group: NYHA class III/IV heart failure, urinary retention, mobility issues, history of renal replacement therapy or kidney transplant, history of cancer treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
Actively Recruiting
Research Team
T
Tekka Johnson
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here